
Praxis Precision (PRAX) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
0
Operating Income
-76.1M
Net Income
-71.1M
EPS (Diluted)
$-3.31
Balance Sheet Metrics
Total Assets
478.7M
Total Liabilities
39.5M
Shareholders Equity
439.2M
Debt to Equity
0.09
Cash Flow Metrics
Operating Cash Flow
-50.1M
Free Cash Flow
-53.0M
Revenue & Profitability Trend
Praxis Precision Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 8.6M | 2.4M | 0 | 0 | 0 |
Cost of Goods Sold | - | - | - | - | - |
Gross Profit | - | - | - | - | - |
Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Operating Expenses | |||||
Research & Development | 152.4M | 86.8M | 155.0M | 120.3M | 45.0M |
Selling, General & Administrative | 56.3M | 42.1M | 59.9M | 47.1M | 17.0M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 208.7M | 128.8M | 215.0M | 167.3M | 62.0M |
Operating Income | -200.2M | -126.4M | -215.0M | -167.3M | -62.0M |
Operating Margin % | -2,340.3% | -5,164.4% | 0.0% | 0.0% | 0.0% |
Non-Operating Items | |||||
Interest Income | - | - | - | - | 140.0K |
Interest Expense | - | - | - | - | - |
Other Non-Operating Income | 17.3M | 3.1M | 957.0K | 271.0K | 140.0K |
Pre-tax Income | -182.8M | -123.3M | -214.0M | -167.1M | -61.8M |
Income Tax | - | - | - | 0 | -8.0K |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -182.8M | -123.3M | -214.0M | -167.1M | -61.8M |
Net Margin % | -2,137.5% | -5,037.9% | 0.0% | 0.0% | 0.0% |
Key Metrics | |||||
EBITDA | -199.8M | -125.9M | -214.6M | -167.2M | -61.9M |
EPS (Basic) | $-10.21 | $-18.69 | $-69.60 | $-59.10 | $-27.56 |
EPS (Diluted) | $-10.21 | $-18.69 | $-69.60 | $-59.10 | $-27.56 |
Basic Shares Outstanding | 17906794 | 6594316 | 3073115 | 2830270 | 2551236 |
Diluted Shares Outstanding | 17906794 | 6594316 | 3073115 | 2830270 | 2551236 |
Income Statement Trend
Praxis Precision Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 215.4M | 81.3M | 61.6M | 138.7M | 296.6M |
Short-term Investments | 177.2M | 0 | 38.9M | 137.2M | 0 |
Accounts Receivable | - | - | - | - | - |
Inventory | - | - | - | - | - |
Other Current Assets | 11.8M | 3.6M | 10.4M | 11.5M | 5.7M |
Total Current Assets | 404.4M | 84.9M | 110.8M | 287.4M | 302.3M |
Non-Current Assets | |||||
Property, Plant & Equipment | 359.0K | 359.0K | 309.0K | 242.0K | 48.0K |
Goodwill | - | - | - | - | - |
Intangible Assets | - | - | - | - | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 416.0K | 416.0K | 416.0K | 472.0K | 15.0K |
Total Non-Current Assets | 78.7M | 3.1M | 4.3M | 5.3M | 851.0K |
Total Assets | 483.1M | 87.9M | 115.1M | 292.7M | 303.2M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 12.5M | 5.8M | 14.7M | 10.8M | 4.1M |
Short-term Debt | 1.3M | 1.1M | 1.0M | 810.0K | 763.0K |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | - | - |
Total Current Liabilities | 37.6M | 15.7M | 34.3M | 38.4M | 15.7M |
Non-Current Liabilities | |||||
Long-term Debt | 110.0K | 1.4M | 2.5M | 3.5M | 0 |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | - | - | - | - | - |
Total Non-Current Liabilities | 110.0K | 2.5M | 4.7M | 3.5M | 0 |
Total Liabilities | 37.7M | 18.3M | 39.0M | 41.9M | 15.7M |
Equity | |||||
Common Stock | 14.0K | 13.0K | 5.0K | 5.0K | 4.0K |
Retained Earnings | -836.7M | -653.9M | -530.6M | -316.6M | -149.6M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 445.4M | 69.7M | 76.1M | 250.8M | 287.5M |
Key Metrics | |||||
Total Debt | 1.4M | 2.5M | 3.5M | 4.3M | 763.0K |
Working Capital | 366.8M | 69.1M | 76.5M | 249.0M | 286.6M |
Balance Sheet Composition
Praxis Precision Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -182.8M | -123.3M | -214.0M | -167.1M | -61.8M |
Depreciation & Amortization | 358.0K | 432.0K | 419.0K | 182.0K | 50.0K |
Stock-Based Compensation | 41.4M | 24.9M | 28.6M | 22.7M | 5.2M |
Working Capital Changes | 3.0M | -12.3M | 8.1M | 6.5M | 269.0K |
Operating Cash Flow | -134.6M | -109.5M | -176.1M | -136.3M | -55.6M |
Investing Activities | |||||
Capital Expenditures | 0 | -50.0K | -444.0K | -1.0M | 0 |
Acquisitions | - | - | - | - | - |
Investment Purchases | -371.5M | 0 | -83.0M | -164.2M | 0 |
Investment Sales | 123.0M | 39.0M | 180.4M | 24.7M | 0 |
Investing Cash Flow | -248.5M | 39.0M | 96.9M | -140.5M | 0 |
Financing Activities | |||||
Share Repurchases | - | - | - | 0 | -30.0M |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | - | - | - | - |
Debt Repayment | - | - | - | - | - |
Financing Cash Flow | 511.7M | 91.5M | 9.0M | 105.1M | 304.3M |
Free Cash Flow | -131.8M | -111.2M | -185.5M | -125.6M | -52.6M |
Net Change in Cash | 128.6M | 20.9M | -70.2M | -171.7M | 248.7M |
Cash Flow Trend
Praxis Precision Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-4.50
Forward P/E
-4.21
Price to Book
2.39
Price to Sales
124.51
PEG Ratio
-4.21
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-3,497.57%
Return on Equity
-60.98%
Return on Assets
-37.98%
Financial Health
Current Ratio
6.31
Debt to Equity
0.19
Beta
2.63
Per Share Data
EPS (TTM)
$-12.40
Book Value per Share
$19.21
Revenue per Share
$0.38
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
prax | 966.8M | -4.50 | 2.39 | -60.98% | 0.00% | 0.19 |
Vertex | 94.0B | 26.03 | 5.47 | 22.77% | 31.86% | 8.89 |
Regeneron | 59.7B | 14.18 | 1.96 | 15.34% | 31.37% | 9.04 |
Harmony Biosciences | 2.0B | 11.03 | 2.54 | 27.58% | 23.42% | 22.43 |
Cg Oncology | 1.9B | -17.62 | 2.58 | -16.58% | 0.00% | 0.15 |
Celcuity | 1.9B | -16.21 | 20.03 | -115.39% | 0.00% | 113.89 |
Financial data is updated regularly. All figures are in the company's reporting currency.